1Loo TW, Clarke DM. Do drug substrates enter thecommon drug-binding pocket of P-glycoprotein through ”gates" [J]? Biochem Biophys Res Commun, 2005,329(2):419 -422.
2Li Z, Hu S, Wang J, et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in humanovarian cancer cells [ J]. Gynecol Oncol,2010,119( 1):125 -130.
3Bai H, Xu R, Cao Z, et al. Involvement of miR-21 inresistance to daunorubicin by regulating PTEN expressionin the leukaemia K562 cell line [ J ]. FEBS Lett,2011,585(2) :402 -408.
4Dong J, Zhao YP, Zhou L,et al. Bel-2 upregulationinduced by miR-21 via a direct interaction is associatedwith apoptosis and chemoresistance in MIA PaCa-2pancreatic cancer cells [J]. Arch Med Res,2011 , 42(1):8-14.'.
5Shi L, Cheng Z, Zhang J, et al. hsa-mir-181 a and hsa-mir-181b function as tumor suppressors in human gliomacells [J]. Brain Res, 2008,1236: 185 - 193.
6Fanini F,Vannini I, Fabbri M. MicroRNAs: tiny playerswith a big role in the pathogenesis of leukemias andlymphomas [ J]. Hematol Rev,2009,1(1) :40 -45.
7Galluzzi L, Morselli E, Vitale L, et al. miR-181a andmiR-630 regulate cisplatin-induced cancer cell death[J]. Cancer Res, 2010,70(5) :1793 - 1803.
8Zhu W, Shan X, Wang T,et al. miR-181b modulatesmultidrug resistance by targeting Bcl2 in human cancercell lines [ J]. Int J Cancer, 2010,127 ( 11 ) : 2520 -2529.
9Chen G,Zhu W, Shi D, et al. MicroRNA-181 asensitizes human malignant glioma U87MG cells toradiation by targeting Bcl-2 [ J]. Oncol Rep, 2010,23(4):997 -1003.
